23andMe (NASDAQ:ME) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a report issued on Saturday,Weiss Ratings reports.

23andMe Price Performance

Shares of NASDAQ:ME remained flat at $3.61 during trading hours on Friday. The company’s stock had a trading volume of 475,228 shares, compared to its average volume of 194,032. The firm has a market cap of $94.29 million, a price-to-earnings ratio of -0.14 and a beta of 1.14. The firm has a 50-day simple moving average of $3.51 and a two-hundred day simple moving average of $5.65. 23andMe has a fifty-two week low of $2.65 and a fifty-two week high of $16.52.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter. The business had revenue of $44.07 million for the quarter, compared to analysts’ expectations of $50.30 million. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.

Hedge Funds Weigh In On 23andMe

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB purchased a new stake in shares of 23andMe in the 4th quarter worth approximately $40,000. FNY Investment Advisers LLC purchased a new stake in 23andMe during the fourth quarter worth $26,000. Geode Capital Management LLC boosted its position in 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after acquiring an additional 28,252 shares in the last quarter. FMR LLC increased its holdings in shares of 23andMe by 24.0% in the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after acquiring an additional 192,099 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of 23andMe in the 3rd quarter worth $805,000. Institutional investors own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.